Fig. 5

Remodeling of immunometabolism. (A) Analysis of calreticulin eversion in CT26 cells by flow cytometry. (B) and (C) Western blot analysis of the released HMGB-1 of CT26 cells and grayscale analysis of HMGB1. (D) Schematic of the ICD stimulated maturation of BMDC. (E) CD80⁺CD86⁺ DC subsets were stimulated by CT26 cells after treatment (LPS: 200 ng/mL; LA: lactate 5 mM). (F) Schematic of ICD activated T cell immunity. (G–I) The CD8⁺T subsets (CD8⁺Ki67⁺) and the cytotoxic substances of CD8⁺T (CD8⁺IFNγ⁺, CD8⁺Granzyme B⁺) (Untreated: CT26 co-incubated with DC and spleen lymphocytes; LPS: 200 ng/mL; LA: 10 mM). Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001